NDATOPICALGEL
Approved
Jul 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAMISIL AT (terbinafine) is a topical antifungal gel approved in 2006 for treating fungal infections including onychomycosis, tinea pedis, tinea capitis, and oral candidiasis. It works by inhibiting fungal ergosterol synthesis, disrupting cell membrane integrity. The product is a small-molecule NDA indicated for dermatological and mycological conditions.
LOE Approaching
As a product approaching loss of exclusivity with moderate competitive pressure (30), career opportunities are shifting toward defensive positioning and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the Toenails
Started Mar 2026
200 enrolled
Onychomycosis of Toenail
Comparative Study Between Pulse Therapy With Oral Itraconazole Versus Continuous Oral Terbinafine Therapy for Treatment of Onychomycosis
Started Mar 2022
100 enrolled
Onychomycosis
To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis
Started Jan 2022
35 enrolled
Onychomycosis of Toenail
Terbinafine Treatment of Axial Spondyloarthropathy
Started Mar 2021
0Ankylosing SpondylitisAxial SpondyloarthritisPsoriatic Spondylitis+2 more
SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS
Started Jan 2019
42 enrolled
Tinea Pedis
Worked on LAMISIL AT at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.